Biotech News

Prime Medicine to Participate in Upcoming Investor Conferences

Prime Medicine (PRME)Prime Medicine2026-02-25 13:00 ESTCompany update

CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in three upcoming conferences: TD

Open original release

Related news

PRMEPrime Medicine2026-06-03 12:00 EST

Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference

PRMEPrime Medicine2026-04-16 12:00 EST

Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer

View all latest news

Prime Medicine

Prime Medicine is a gene-editing company focused on prime-editing technology for a broad set of genetic diseases. The platform aims to expand the precision and flexibility of genome editing.

Recent company news

PRMEPrime Medicine2026-06-03 12:00 EST

Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference

PRMEPrime Medicine2026-05-07 12:00 EST

Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates

PRMEPrime Medicine2026-04-16 12:00 EST

Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer

PRMEPrime Medicine2026-03-03 13:00 EST

Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates

PRMEPrime Medicine2026-02-25 13:00 EST

Prime Medicine to Participate in Upcoming Investor Conferences

Stock data

Close: 3.01 USD
Market cap: 579.78M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States